Literature DB >> 8245109

Preliminary evaluation of vibriolysin, a novel proteolytic enzyme composition suitable for the debridement of burn wound eschar.

D R Durham1, D Z Fortney, L B Nanney.   

Abstract

Vibriolysin, a proteolytic enzyme secreted by the marine microorganism Vibrio proteolyticus, was evaluated for its efficacy as an enzymatic debridement agent. Initial in vitro experiments revealed that the protease readily hydrolyzed proteinaceous components of eschar (e.g., fibrin, elastin, and in particular, collagen). Enzyme selectivity towards the digestion of denatured proteins but not viable elements was demonstrated in vitro and in vivo by treatment of full-thickness burn wounds with a porcine model. The full-thickness wound eschar was rapidly hydrolyzed by a hydrophilic vibriolysin composition with a resultant wound bed that appeared pink and viable. Vibriolysin exhibited desirable properties heretofore not described for the enzymatic debridement agents, in particular, its selective hydrolysis of dead but not viable tissue, debridement in the absence of bleeding, compatibility with adjunct therapies, and its unique shelf-life stability in a hydrophilic composition at ambient temperature.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8245109     DOI: 10.1097/00004630-199309000-00009

Source DB:  PubMed          Journal:  J Burn Care Rehabil        ISSN: 0273-8481


  3 in total

Review 1.  Comparing the reported burn conditions for different severity burns in porcine models: a systematic review.

Authors:  Christine J Andrews; Leila Cuttle
Journal:  Int Wound J       Date:  2017-07-23       Impact factor: 3.315

2.  Historical Perspectives on the Development of Current Standards of Care for Enzymatic Debridement.

Authors:  Wolfram Heitzmann; Paul Christian Fuchs; Jennifer Lynn Schiefer
Journal:  Medicina (Kaunas)       Date:  2020-12-17       Impact factor: 2.430

3.  Histological Studies on a Newly Isolated Bacillus subtilis D10 Protease in the Debridement of Burn Wound Eschars Using Mouse Model.

Authors:  Ibtesam Al-Dhuayan; Essam Kotb; Amany Alqosaibi; Amal Mahmoud
Journal:  Pharmaceutics       Date:  2021-06-22       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.